NASDAQ
12.74USD
+0.80 (+6.65%)
We have scored 10 news catalysts on Amarin Corporation plc (AMRN) over the past 12 months. The biggest single-day move next to one of them came Jan 22, 2026, when AMRN closed +8.0%: “BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?”. Coverage across the window leans positive (average ticker sentiment +0.17). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
263.6M
P/E
—
EPS
—
Beta
0.77
52W range
11.25-18.5
Day range
12.10–13.01
Open
12.69
Prev close
11.95
Volume
161.3K
Avg volume
70.2K
Dividend
0.00
IPO
1993-04-01
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Amarin Corporation plc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AMRN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
